The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Nitecapona     3-[(3,4-dihydroxy-5-nitro...

Synonyms: Nitecapone, Nitecaponum, AC1NUYYN, CHEMBL167055, SureCN128420, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Nitecapone

  • The combined results suggest that the COMT-inhibitory and antioxidant properties of nitecapone provide a protective therapy against the development of diabetic nephropathy [1].
  • Hyperfiltration, focal glomerulosclerosis, and albuminuria were also reversed by nitecapone, but in a manner that is more readily attributed to the antioxidant potential of the agent [1].
  • Altogether, three patients with Parkinson's disease (PD) and three normal volunteers were examined, first without nitecapone and then with an oral dose of 100 mg of nitecapone 1 hour before the IV injection of 3 mCi of [18F]6-fluorodopa [2].
  • In the present study, the influence of nitecapone on isolated rat heart ischemia-reperfusion injury was investigated to elucidate its cardioprotective role [3].
  • Behaviorally DM induced mechanical hypersensitivity that was markedly attenuated by oral treatment with nitecapone [4].

High impact information on Nitecapone


Chemical compound and disease context of Nitecapone


Biological context of Nitecapone


Anatomical context of Nitecapone


Associations of Nitecapone with other chemical compounds


Gene context of Nitecapone


Analytical, diagnostic and therapeutic context of Nitecapone


  1. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Lal, M.A., Körner, A., Matsuo, Y., Zelenin, S., Cheng, S.X., Jaremko, G., DiBona, G.F., Eklöf, A.C., Aperia, A. Diabetes (2000) [Pubmed]
  2. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Laihinen, A., Rinne, J.O., Rinne, U.K., Haaparanta, M., Ruotsalainen, U., Bergman, J., Solin, O. Neurology (1992) [Pubmed]
  3. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Haramaki, N., Stewart, D.B., Aggarwal, S., Kawabata, T., Packer, L. Biochem. Pharmacol. (1995) [Pubmed]
  4. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Pertovaara, A., Wei, H., Kalmari, J., Ruotsalainen, M. Exp. Neurol. (2001) [Pubmed]
  5. Endogenous dopamine and duodenal bicarbonate secretion in humans. Knutson, L., Knutson, T.W., Flemström, G. Gastroenterology (1993) [Pubmed]
  6. Inhibition of the oxidative modification of LDL by nitecapone. Pentikäinen, M.O., Lindstedt, K.A., Kovanen, P.T. Arterioscler. Thromb. Vasc. Biol. (1995) [Pubmed]
  7. Antioxidant properties of nitecapone (OR-462). Suzuki, Y.J., Tsuchiya, M., Safadi, A., Kagan, V.E., Packer, L. Free Radic. Biol. Med. (1992) [Pubmed]
  8. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Cedarbaum, J.M., Leger, G., Guttman, M. Clinical neuropharmacology. (1991) [Pubmed]
  9. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of nitecapone. Slomiany, B.L., Piotrowski, J., Rajiah, G., Slomiany, A. Gen. Pharmacol. (1991) [Pubmed]
  10. Protection against alcohol-induced gastric mucosal injury by nitecapone. Slomiany, B.L., Piotrowski, J., Ismail, A., Rajiyah, G., Tamura, S., Bielanski, W., Slomiany, A. Gen. Pharmacol. (1991) [Pubmed]
  11. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Sundberg, S., Scheinin, M., Ojala-Karlsson, P., Kaakkola, S., Akkila, J., Gordin, A. Clin. Pharmacol. Ther. (1990) [Pubmed]
  12. Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. Helkamaa, T., Männistö, P.T., Rauhala, P., Cheng, Z.J., Finckenberg, P., Huotari, M., Gogos, J.A., Karayiorgou, M., Mervaala, E.M. J. Hypertens. (2003) [Pubmed]
  13. Nitecapone reduces cardiac neutrophil accumulation in clinical open heart surgery. Pesonen, E.J., Vento, A.E., Rämo, J., Vuorte, J., Jansson, S.E., Repo, H. Anesthesiology (1999) [Pubmed]
  14. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Schultz, E., Nissinen, E. Biochem. Pharmacol. (1989) [Pubmed]
  15. Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain. Männistö, P.T., Törnwall, M., Tuomainen, P., Borisenko, S.A., Tuominen, R.K. Neuroreport (1992) [Pubmed]
  16. Extending levodopa action: COMT inhibition. Martínez-Martín, P., O'Brien, C.F. Neurology (1998) [Pubmed]
  17. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Lal, M.A., Brismar, H., Eklöf, A.C., Aperia, A. Kidney Int. (2002) [Pubmed]
  18. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Nissinen, E., Lindén, I.B., Schultz, E., Kaakkola, S., Männistö, P.T., Pohto, P. Eur. J. Pharmacol. (1988) [Pubmed]
  19. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. Lindén, I.B., Nissinen, E., Etemadzadeh, E., Kaakkola, S., Männistö, P., Pohto, P. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  20. Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting. Vento, A.E., Aittomäki, J., Verkkala, K.A., Heikkilä, L.J., Salo, J.A., Sipponen, J., Rämö, O.J. Ann. Thorac. Surg. (1999) [Pubmed]
WikiGenes - Universities